Collateral Estoppel Does Not Apply When the Prior Proceeding Applies a Lower Burden of Proof
Contributed by Knobbe Martens. Originally published on Patexia; republished here as part of the LexDana archive.
Written by: Justin K. Theam and Kendall Loebbaka
KROY IP HOLDINGS, LLC v. GROUPON, INC.
Before Prost, Reyna, and Taranto. Appeal from the U.S. District Court for the District of Delaware.
Summary: Because there are different burdens of proof in IPRs and district court, collateral estoppel does not preclude a patent owner from asserting claims that are immaterially different from claims canceled in an IPR.
Kroy IP Holdings (Kroy) sued Groupon for patent infringement. Groupon filed two IPR petitions against the asserted patent, challenging only some of the claims. The Patent Trial and Appeal Board (the “Board”) found all challenged claims unpatentable, which the Federal Circuit affirmed. However, after the deadline for Groupon to file IPRs had passed, Kroy amended its complaint to include additional claims not challenged in the IPRs. Groupon moved to dismiss, arguing Kroy was collaterally estopped because of the two prior IPR decisions. The district court granted the motion, finding that collateral estoppel prevents a patent owner from asserting immaterially different claims. Kroy appealed.
The Federal Circuit reversed, holding collateral estoppel does not apply when the second action involves a different legal standard, such as a different burden of proof. At the district court, Groupon had to prove invalidity by clear and convincing evidence. However, before the Board, Groupon was required to prove unpatentability only by a preponderance of the evidence. Accordingly, the Federal Circuit reversed and remanded.
Editor: Sean Murray
More insights
The Prosecution Data Most IP Attorneys Never Look At
Most prosecution strategy is set before anyone looks at who is actually examining the application. What is sitting there unused Every examiner has a history: allowance rate, average number of office actions, how often an interview changes the outcome. None…
Federal Circuit Affirms Invalidation of Patent for Lack of Enablement of Claims Directed to a Method of Treating a Patient with a Unit Dosage in Wyeth Llc v Astrazeneca Pharmaceuticals Lp
Written by : Eric Furman, Ph.D. and Ashley C. Morales Key Takeaway: Federal Circuit invalidates patent claims directed to a method for treating non-small cell lung cancer through administration of “a unit dosage” of an irreversible epidermal…
When About Becomes Indefinite Federal Circuit Provides Guidance for Life Science Patent Applications Regarding Limits of Approximation in Enviro Tech v Safe Foods
Written by : Jason J. Jardine and Kenneth O. Aruda, Ph.D. Key Takeaway: The term “about” remains useful in biotech and pharmaceutical claims, but only if the patent provides objective guidance about what the term means. Absent that guidance,…